3.06
-0.15 (-4.53%)
| Penutupan Terdahulu | 3.20 |
| Buka | 3.21 |
| Jumlah Dagangan | 27,735 |
| Purata Dagangan (3B) | 189,771 |
| Modal Pasaran | 113,590,952 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Nov 2026 |
| Margin Keuntungan | -9.07% |
| Margin Operasi (TTM) | -1,668.23% |
| EPS Cair (TTM) | -0.400 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -49.20% |
| Nisbah Semasa (MRQ) | 0.120 |
| Aliran Tunai Operasi (OCF TTM) | -34.55 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -30.48 M |
| Pulangan Atas Aset (ROA TTM) | -24.32% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Armata Pharmaceuticals, Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -2.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | -2.5 |
| AI Insight | NA |
| Purata | 0.17 |
|
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 69.55% |
| % Dimiliki oleh Institusi | 2.13% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Dauntless Investment Group, Llc | 30 Jun 2026 | 203,891 |
| Edgewood Management Llc | 30 Jun 2026 | 80,000 |
| Grey Ledge Advisors, Llc | 30 Jun 2026 | 50,000 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
AI Analisis Teknikal
Buka tab Teknikal untuk menjana analisis terkini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |